Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00788294 · ClinicalTrials.gov registry record · Phase 1
Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
A Phase 1 study of Healthy Volunteers, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT00788294: Completed Phase 1 study of Healthy Volunteers, sponsored by Pfizer.
NCT00788294 is a Phase 1 study of Healthy Volunteers that has completed, run by Pfizer. The registered enrollment target is 76 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00788294, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.
Conditions Studied
Interventions
- BIOLOGICAL tanezumab
Study Locations (1)
California
- Pfizer Investigational Site - Cypress
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 1 |
What the finished NCT00788294 record still lists
NCT00788294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which tanezumab is the first listed.
NCT00788294 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00788294 about?
NCT00788294 is a clinical study titled "Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously". The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.
What is the current status of trial NCT00788294?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2008-11. Estimated completion is 2009-06.
What conditions does trial NCT00788294 study?
This clinical trial studies the following conditions: Healthy Volunteers.
What interventions are being tested in trial NCT00788294?
The interventions under investigation include: tanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00788294?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00788294 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00788294's enrollment target sits among peer trials
76 90th of 283 higher than 193 of 283 other Healthy Volunteers trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Volunteers trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia